当前位置:
首页
>
产品中心 >
clinical_research >
absoluteantibody/Ab00447-10.0 Anti-CD40L [hu5c8 (Ruplizumab)]/Ab00447-10.0/ 200 µg
absoluteantibody/Ab00447-10.0 Anti-CD40L [hu5c8 (Ruplizumab)]/Ab00447-10.0/ 200 µg
商品编号:
Ab00447-10.0
品牌:
absoluteantibody
市场价:
¥5400.00
美元价:
3240.00
产品分类:
临床研究
公司分类:
clinical_research
联系Q Q:
3392242852
电话号码:
4000-520-616
电子邮箱:
info@ebiomall.com
商品介绍
Description: Recombinant monoclonal antibody to CD40L. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma hu5c8 (Ruplizumab).
Clone Number: hu5c8 (Ruplizumab)
UniProt Accession Number of Target Protein: P29965
Alternative Name(s) of Target: CD40 ligand; tumour necrosis factor ligand superfamily member 5; TNFSF5; CD154; tumour necrosis factor related activation protein; TRAP.
Published Application(s): Block; FC; WB
Published Species Reactivity: Human
Immunogen: Human CD40L
Specificity: The antibody binds to CD40L with an IC50 of 0.845 ug/ml.
Application Notes: The antibody binds specifically to CD40L, a surface receptor expressed on activated T cells which acts as a costimulatory molecule to trigger immune responses. The antibody neutralises CD40L function, as it blocks the interaction between CD40 and CD40L. When injected into cynomolgus monkeys, the original therapeutic antibody was found to have a T1/2 of 531? ±?155 hours.
Antibody First Published in:
Karpusas et al. Structure of CD40 Ligand in Complex with the Fab Fragment of a Neutralizing Humanized Antibody Structure. 2001 Apr 4;9(4):321-9. PMID:11525169 Note on publication: Describes the role of CD40-CD40L interaction in immune responses and pathologies. Also describes the generation of humanized monoclonal antibodies against CD40L and the use of a crystal structure to determine its binding.
Concentration: See vial label.
Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic
procedures for humans or animals.NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.
Species and Isotype: Human IgG1, kappaClone Number: hu5c8 (Ruplizumab)
UniProt Accession Number of Target Protein: P29965
Alternative Name(s) of Target: CD40 ligand; tumour necrosis factor ligand superfamily member 5; TNFSF5; CD154; tumour necrosis factor related activation protein; TRAP.
Published Application(s): Block; FC; WB
Published Species Reactivity: Human
Immunogen: Human CD40L
Specificity: The antibody binds to CD40L with an IC50 of 0.845 ug/ml.
Application Notes: The antibody binds specifically to CD40L, a surface receptor expressed on activated T cells which acts as a costimulatory molecule to trigger immune responses. The antibody neutralises CD40L function, as it blocks the interaction between CD40 and CD40L. When injected into cynomolgus monkeys, the original therapeutic antibody was found to have a T1/2 of 531? ±?155 hours.
Antibody First Published in:
Karpusas et al. Structure of CD40 Ligand in Complex with the Fab Fragment of a Neutralizing Humanized Antibody Structure. 2001 Apr 4;9(4):321-9. PMID:11525169 Note on publication: Describes the role of CD40-CD40L interaction in immune responses and pathologies. Also describes the generation of humanized monoclonal antibodies against CD40L and the use of a crystal structure to determine its binding.
Product Form
Purification: Protein A affinity purified Supplied in: PBS only.
Storage Recommendation: Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°CConcentration: See vial label.
品牌介绍
Absolute antibody本公司服务于抗体测序、制造和工程服务提供给所有抗体使用者和不断增长的抗体。Absolute Antibody Ltd was founded in Oxford, UK, in August 2012, with the vision that all antibody users should be able to use recombinant antibodies, which are absolutely defined by their amino acid sequence. This view gained support in 2015 with a Comment in Nature magazine by Bradbury and Pluckthun (+110 co-signatories) – “Reproducibility: Standardize antibodies used in research“. Rather than creating entirely new antibodies (or antibody-like molecules), we are building a catalog by taking existing antibodies (often from hybridomas) then manufacturing them in a superior way and improving their usefulness by engineering.品牌货号名称规格absoluteantibody21 E11Anti-Api m 21 kitabsoluteantibodyBAB2Anti-Bet v 1 1 kitabsoluteantibodyBAB3Anti-Bet v 11 kitabsoluteantibodyBAB4Anti-Bet v 11 kitabsoluteantibodyBAB5Anti-Bet v 1 1 kitabsoluteantibodyBV16Anti-Bet v 1 1 kitabsoluteantibodyM0418Anti-Bet v 11 kitabsoluteantibody4C3Anti-Bla g 2 1 kitabsoluteantibody7C11Anti-Bla g 21 kitabsoluteantibodyD1Anti-Bos d 5 1 kitabsoluteantibody6A8Anti-Der f 11 kitabsoluteantibody10B9Anti-Der p 11 kitabsoluteantibody5H8Anti-Der p 11 kitabsoluteantibody4C1Anti-Neurotoxin AahII1 kitabsoluteantibodyH10Anti-Der p 21 kit
品牌分类
关注表位标记
Primary Antibodies
Recombinant Antibodies from Human Patients
Anti-Allergen Antibodies
多标签控制蛋白
Recombinant Isotype Controls
抗过敏原抗体
重组F4/80克隆CI:A3-1
体内研究用重组抗体
联络我们
服务热线:4000-520-616
(限工作日9:00-18:00)
QQ :1570468124
手机:18915418616